ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK EBITDA Margin

EBITDA as a percentage of revenue.

ProKidney Corp.NASDAQ: PROK

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -18217.3%

EBITDA Margin was -18217.3% in Q1 FY2026, down 2669.0 pp from a year earlier. On a trailing-twelve-month basis it was -16919.8%, up 35407.7 pp year over year.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -14170.4% for the fiscal year ending Dec 2026, up from -16194.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-18217.3%-0.8 pp QoQ
Last fiscal yearDec 2025
-16194.7%+192347.4 pp YoY
LTMMar 2026
-16919.8%+35407.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2669.0 pp+963.8 pp+3632.8 pp
1 year+192347.4 pp+2024.4 pp-190323.0 pp
3 years—+15663.5 pp—
5 years+16201.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-16194.7%
Year-over-year change
+192347.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 EBITDA Margin of -16919.8% is the lowest of the 4 companies compared; the peer median is -16.4%.
  • Its year-over-year change of +35407.7 pp is the highest of 4, against a peer median of -11.2 pp.
PROK Competitors Peer median
EBITDA Margin for PROK and competitors
Company Period LTM level YoY 3-year change
ARDXArdelyx, Inc.LTM Mar 2026-6.0% +1.8 pp+109.8 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-16.4% -11.2 pp+278.1 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-597.6% -631.1 pp—
PROKProKidney Corp.LTM Mar 2026-16919.8% +35407.7 pp—
DMACDiaMedica Therapeutics Inc.FY2025— ——
MENSJyong Biotech Ltd. Ordinary SharesFY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
Peer median (excluding PROK) -16.4%-11.2 pp+193.9 pp

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00076K893K
Cost of Revenue00000
Gross Profit00076K893K
Gross Margin———100.0%100.0%
Research & Development46.26M82.07M106.71M127.67M114.12M
Selling, General & Admin8.86M70.94M44.82M56.08M51.78M
Operating Expenses55.11M153.01M151.52M183.75M165.9M
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
EBITDA(53.12M)(143.99M)(125.59M)(158.49M)(144.62M)
EBITDA Margin———-208542.1%-16194.7%
Operating Income(55.11M)(153.01M)(151.52M)(183.68M)(165.01M)
Operating Margin———-241678.9%-18477.8%
Interest Income2K5.98M22.08M19.75M13.81M
Interest Expense0215K12K9K4K
Other Income / Expenses2K5.77M22.07M19.74M13.81M
Income Before Tax(55.11M)(147.24M)(129.45M)(163.93M)(151.2M)
Pre-Tax Margin———-215701.3%-16931.5%
Income Tax Expense38K896K6M(598K)414K
Net Income(55.15M)(108.03M)(35.47M)(61.19M)(68.99M)
Net Margin———-80507.9%-7725.2%
EPS (Basic)(1.73)(1.76)(0.57)(0.62)(0.52)
EPS (Diluted)(1.73)(1.76)(0.57)(0.62)(0.52)
Weighted Avg Shares31.89M61.54M61.71M97.92M133.94M
Weighted Avg Shares (Diluted)31.89M61.54M61.71M97.92M133.94M

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.